Cerus (CERS) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.01
- Surprise
- +100.0%
- Revenue (period 2026-09-30)
- $57.7M
- Score today
- 5.7/10
Revenue source: xbrl.
Coverage in the report window
- Why Aehr Test Systems Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket — benzinga, 2026-11-03
- Cerus Q3 2026 Earnings Call Transcript — benzinga, 2026-11-02
- Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial — fiscal.ai, 2026-11-02
Where TrendMatrix's rating stands now
TrendMatrix currently rates CERS Sell at 5.7/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's +100.0% surprise compares with a +23.8% four-quarter average.
What argues against it
- Concentration risk — Supplier: Fresenius Kabi
- Concentration risk — Customer: American Red Cross
- Quality below floor (3.1 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $2.36
- Price target
- $4.36
- Stop
- $2.19
- Upside to target
- +84.7%
- Reward-to-risk
- 8.3:1
Risk check: trading volume is running 2.1× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-03 — shown for context, not personalized investment advice.
CERS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $475.6M
- P/E (fwd)
- -472.0
- 52-week range
- $1.38–$3.47
- Off 52-week high
- 32.0%
- RSI (14)
- 56
- Volume vs avg
- 2.09×
- Score today
- 5.7/10